Examination of sulfonamide-based inhibitors of MMP3 using the conditioned media of invasive glioma cells

References

• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–547.
   PubMed Web of Science ®Google Scholar
• Legler JM, Ries LAG, Smith MA, et al. Brain and other central nervous system cancers: recent trends in incidence and mortality. JNCI-J Natl Cancer Inst 1999;91:1382–90.
   Web of Science ®Google Scholar
• Lee J, Hoxha E, Song HR. A novel NFIA-NFκB feed-forward loop contributes to glioblastoma cell survival. Neuro-Oncology 2017;19:524–34.
   PubMed Web of Science ®Google Scholar
• Roth W, Isenmann S, Nakamura M, et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res. 2001;61:2759–65.
   PubMed Web of Science ®Google Scholar
• Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21:2683–710.
   PubMed Web of Science ®Google Scholar
• Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 2012;149:36–47.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803–20.
   PubMed Web of Science ®Google Scholar
• Nonoguchi N, Ohta T, Oh JE, et al. TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 2013;126:931–7.
   PubMed Web of Science ®Google Scholar
• Wick W, Stupp R, Beule AC, et al. A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro-Oncology 2008;10:1019–24.
   PubMed Web of Science ®Google Scholar
• Rapp M, Baernreuther J, Turowski B, et al. Recurrence pattern analysis of primary glioblastoma. World Neurosurg 2017;103:733–40.
   PubMed Web of Science ®Google Scholar
• Sherriff J, Tamangani J, Senthil L, et al. Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br J Radiol 2013;86:20120414.
   PubMed Web of Science ®Google Scholar
• Bates DC, Sin WC, Aftab Q, Naus CC. Connexin43 enhances glioma invasion by a mechanism involving the carboxy terminus. Glia 2007;55:1554–64.
   PubMed Web of Science ®Google Scholar
• Naus CC, Aftab Q, Sin WC. Common mechanisms linking connexin43 to neural progenitor cell migration and glioma invasion. Semin Cell Dev Biol 2016;50:59–66.
   PubMed Web of Science ®Google Scholar
• Kameritsch P, Pogoda K, Pohl U. Channel-independent influence of connexin 43 on cell migration. Biochim Biophys Acta 2012;1818:1993–2001.
   PubMed Web of Science ®Google Scholar
• Oliveira R, Christov C, Guillamo JS, et al. Contribution of gap junctional communication between tumor cells and astroglia to the invasion of the brain parenchyma by human glioblastomas. BMC Cell Biol 2005;6:7.
   PubMedGoogle Scholar
• Sin WC, Aftab Q, Bechberger JF, et al. Astrocytes promote glioma invasion via the gap junction protein connexin43. Oncogene 2016;35:1504–16.
   PubMed Web of Science ®Google Scholar
• Aftab Q, Sin WC, Naus CC. Reduction in gap junction intercellular communication promotes glioma migration. Oncotarget 2015;6:11447–64.
   PubMedGoogle Scholar
• Aftab Q, Mesnil M, Ojefua E, et al. Cx43-associated secretome and interactome reveal synergistic mechanisms for glioma migration and MMP3 activation. Front Neurosci 2019;13:143.
   PubMed Web of Science ®Google Scholar
• Jin X, Jin X, Sohn YW, et al. Blockade of EGFR signaling promotes glioma stem-like cell invasiveness by abolishing ID3-mediated inhibition of p27(KIP1) and MMP3 expression. Cancer Lett 2013;328:235–42.
   PubMed Web of Science ®Google Scholar
• Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 2002;3:509–19.
   PubMed Web of Science ®Google Scholar
• Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002;2:657–72.
   PubMed Web of Science ®Google Scholar
• Friedl P, Wolf K. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res 2008;68:7247–9.
   PubMed Web of Science ®Google Scholar
• Ren F, Tang R, Zhang X, et al. Overexpression of MMP family members functions as prognostic biomarker for breast cancer patients: a systematic review and meta-analysis. PLoS One 2015;10:e0135544.
   PubMed Web of Science ®Google Scholar
• Sun DW, Zhang YY, Qi Y, et al. Prognostic significance of MMP-7 expression in colorectal cancer: a meta-analysis. Cancer Epidemiol 2015;39:135–42.
   PubMed Web of Science ®Google Scholar
• Gong L, Wu D, Zou J, et al. Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016;7:18458–68.
   PubMedGoogle Scholar
• Jia H, Zhang Q, Liu F, Zhou D. Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis. Arch Gynecol Obstet 2017;295:689–96.
   PubMed Web of Science ®Google Scholar
• Mehner C, Miller E, Nassar A, et al. Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes Cancer 2015;6:480–9.
   PubMedGoogle Scholar
• Auge F, Hornebeck W, Laronze JY. A novel strategy for designing specific gelatinase A inhibitors: potential use to control tumor progression. Crit Rev Oncol/Hematol 2004;49:277–82.
   PubMed Web of Science ®Google Scholar
• Cerofolini L, Fragai M, Luchinat C. Mechanism and inhibition of matrix metalloproteinases. Curr Med Chem 2019;26:2609–33.
   PubMed Web of Science ®Google Scholar
• Locasale JW, Grassian AR, Melman T, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011;43:869–74.
   PubMed Web of Science ®Google Scholar
• Verma RP. Hydroxamic acids as matrix metalloproteinase inhibitors. Exp Suppl 2012;103:137–76.
   PubMedGoogle Scholar
• Puerta DT, Griffin MO, Lewis JA, et al. Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency, toxicity, and reactivity. J Biol Inorg Chem 2006;11:131–8.
   PubMed Web of Science ®Google Scholar
• Breuer E, Frant J, Reich R. Recent non-hydroxamate matrix metalloproteinase inhibitors. Expert Opin Ther Patents 2005;15:253–69.
   Web of Science ®Google Scholar
• Pikul S, Ohler NE, Ciszewski G, et al. Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases. J Med Chem 2001;44:2499–502.
   PubMed Web of Science ®Google Scholar
• Farkas E, Katz Y, Bhusare S, et al. Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group. J Biol Inorg Chem 2004;9:307–15.
   PubMed Web of Science ®Google Scholar
• Wang X, Choe Y, Craik CS, Ellman JA. Design and synthesis of novel inhibitors of gelatinase B. Bioorg Med Chem Lett 2002;12:2201–4.
   PubMed Web of Science ®Google Scholar
• Whittaker M, Floyd CD, Brown P, Gearing AJH. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999;99:2735–76.
   PubMed Web of Science ®Google Scholar
• Lin KZ, Zhang QW, Liu ZZ, et al. Effects of suberoylanilide hydroxamic acid on rat cytochrome P450 enzyme activities. Int J Clin Exp Pathol 2015;8:5584–90.
   PubMed Web of Science ®Google Scholar
• McGee-Lawrence ME, McCleary-Wheeler AL, Secreto FJ, et al. Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone 2011;48:1117–26.
   PubMed Web of Science ®Google Scholar
• Rosenbaum E, Zahurak M, Sinibaldi V, et al. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clin Cancer Res 2005;11:4437–43.
   PubMed Web of Science ®Google Scholar
• Evans JD, Stark A, Johnson CD, et al. A phase II trial of marimastat in advanced pancreatic cancer. Br J Can 2001;85:1865–70.
   PubMed Web of Science ®Google Scholar
• Fields GB. The rebirth of matrix metalloproteinase inhibitors: moving beyond the dogma. Cells 2019;8:984.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov 2014;13:904–27.
   PubMed Web of Science ®Google Scholar
• Mercapide J, De Cicco RL, Castresana JS, Klein-Szanto AJP. Stromelysin-1/matrix metalloproteinase-3 (MMP-3) expression accounts for invasive properties of human astrocytoma cell lines. Int J Cancer 2003;106:676–82.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem 2000;43:3677–87.
   PubMed Web of Science ®Google Scholar
• Apaydin S, Torok M. Sulfonamide derivatives as multi-target agents for complex diseases. Bioorg Med Chem Lett 2019;29:2042–50.
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE), C. C. G. I., 1010 Sherbrooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2016.
   Google Scholar
• Belviso BD, Caliandro R, Siliqi D, et al. Structure of matrix metalloproteinase-3 with a platinum-based inhibitor. Chem Commun (Camb) 2013;49:5492–4.
   PubMed Web of Science ®Google Scholar
• Jacobsen JA, Major Jourden JL, Miller MT, Cohen SM. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta 2010;1803:72–94.
   PubMed Web of Science ®Google Scholar
• Grobben B, De Deyn PP, Slegers H. Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res 2002;310:257–70.
   PubMed Web of Science ®Google Scholar
• Zheng X, Shen G, Yang X, Liu W. Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res 2007;67:3691–7.
   PubMed Web of Science ®Google Scholar
• Beljebbar A, Dukic S, Amharref N, Manfait M. Ex vivo and in vivo diagnosis of C6 glioblastoma development by Raman spectroscopy coupled to a microprobe. Anal Bioanal Chem 2010;398:477–87.
   PubMed Web of Science ®Google Scholar
• Naus CC, Zhu D, Todd SD, Kidder GM. Characteristics of C6 glioma cells overexpressing a gap junction protein. Cell Mol Neurobiol 1992;12:163–75.
   PubMed Web of Science ®Google Scholar
• Nagase H, Fields CG, Fields GB. Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). J Biol Chem 1994;269:20952–7.
   PubMed Web of Science ®Google Scholar
• Bernardo MM, Brown S, Li ZH, et al. Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J Biol Chem 2002;277:11201–7.
   PubMed Web of Science ®Google Scholar
• Brown S, Bernardo MM, Li ZH, et al. Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 2000;122:6799–800.
   Web of Science ®Google Scholar
• Campbell DA, Xiao XY, Harris D, et al. Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors. Bioorg Med Chem Lett 1998;8:1157–62.
   PubMed Web of Science ®Google Scholar
• Ikejiri M, Bernardo MM, Bonfil RD, et al. Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem 2005;280:33992–4002.
   PubMed Web of Science ®Google Scholar
• Ikejiri M, Bernardo MM, Meroueh SO, et al. Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem 2005;70:5709–12.
   PubMed Web of Science ®Google Scholar
• Lee M, Bernardo MM, Meroueh SO, et al. Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. Org Lett 2005;7:4463–5.
   PubMed Web of Science ®Google Scholar
• Lutz J, Yao YS, Song EW, et al. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 2005;79:655–61.
   PubMed Web of Science ®Google Scholar
• Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012;196:395–406.
   PubMed Web of Science ®Google Scholar
• Giese A. Glioma invasion-pattern of dissemination by mechanisms of invasion and surgical intervention, pattern of gene expression and its regulatory control by tumorsuppressor p53 and proto-oncogene ETS-1. Acta Neurochir Suppl 2003;88:153–62.
   PubMedGoogle Scholar
• Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery 1996;39:235–50.
   PubMed Web of Science ®Google Scholar
• Zhu D, Caveney S, Kidder GM, Naus CC. Transfection of C6 glioma cells with connexin 43 cDNA:analysis of expression, intercellular coupling, and cell proliferation. Proc Natl Acad Sci USA 1991;88:1883–7.
   PubMed Web of Science ®Google Scholar
• Huang RP, Fan Y, Hossain MZ, et al. Reversion of the neoplastic phenotype of human glioblastoma cells by connexin 43 (cx43). Cancer Res 1998;58:5089–96.
   PubMed Web of Science ®Google Scholar
• Fu CT, Bechberger JF, Ozog MA, et al. CCN3 (NOV) interacts with connexin43 in C6 glioma cells: possible mechanism of connexin-mediated growth suppression. J Biol Chem 2004;279:36943–50.
   PubMed Web of Science ®Google Scholar